Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Lyme disease is a bacterial infection caused by spirochetes of the Borrelia species, specifically the Borrelia burgdorferi (Bb) strain (sensu lato), which can affect multiple organs. It can be categorized into early localized, early disseminated, or late stages, with the body's innate and adaptive immune systems playing a role in generating an inflammatory response that leads to clinical symptoms. Regardless of the stage, most patients treated with appropriate antibiotics significantly improve. Clinical manifestations differ according to the stage of the disease and can include symptoms such as erythema migrans, carditis, central nervous system involvement, and arthritis. However, most patients experience relief from their clinical symptoms when treated with the right antimicrobials.

·       In the United States, the incidence of Lyme disease varies between 8 and 11.5 cases per 100,000 people.

 

Thelansis’s “Lyme Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lyme Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Lyme Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Lyme Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Lyme Disease, Lyme Disease market outlook, Lyme Disease competitive landscape, Lyme Disease market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)